Figure 1.

Waterfall plot for individual trial participants allocated to rosuvastatin 20 mg for the per cent change in low-density lipoprotein cholesterol (left) and concordant incident event rates (per 1000 person-years) for the Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin primary endpoint (right). Data are shown for the placebo group (white bars) and for those allocated to rosuvastatin who had no reduction or an increase in low-density lipoprotein cholesterol (pink), a >0 but <50% reduction in low-density lipoprotein cholesterol (light green), and a ≥50% reduction in low-density lipoprotein cholesterol (dark green).